An abbreviated one month course of dual antiplatelet therapy is an acceptable antithrombotic strategy for patients undergoing percutaneous coronary intervention (PCI) with a drug-eluting stent at high bleeding risk, a trial has shown. Presented at ESC Congress 2021, results from the MASTER DAPT study showed that 30 days of dual antiplatelet therapy (DAPT) was noninferior ...
Shorter dual antiplatelet strategy suitable for high risk patients receiving drug eluting stents
By Michael Woodhead
31 Aug 2021